GlassScriptPhysician profile
Tara A Hart
NPI 1134726284
$1,762.89
in general payments reported to CMS, 2019-2025
25 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $636 · 2024: $498 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.27 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $213.42 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $179.28 | 2023-2024 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $167.49 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Vanda Pharmaceuticals INC. | $152.70 | 2025 | Fanapt, Hetlioz |
| Gilead Sciences, INC. | $97.83 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $84.23 | 2023-2024 | Rexulti, Abilify Maintena |
| Xeris Pharmaceuticals, INC. | $71.61 | 2022-2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $61.69 | 2023 | Gemtesa |
| Alkermes, INC. | $47.11 | 2023-2025 | Vivitrol, Vivitrol |
| Amgen INC. | $42.83 | 2023 | Evenity, Prolia |
| Ultragenyx Pharmaceutical INC. | $23.37 | 2022 | |
| Amryt Pharma Holdings LTD | $19.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.18 | 2023 | Xarelto |
| Medtronic, INC. | $16.80 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $15.93 | 2023 | Contrave |
| Cipher Pharmaceuticals US LLC | $15.87 | 2025 | Spinosad, Natroba |
| Impel Pharmaceuticals INC. | $15.75 | 2022 | |
| Dexcom, INC. | $15.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.44 | 2023 | |
| Recordati_rare_diseases_inc. | $14.06 | 2023 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.17 | 2023 | Jardiance |
| Astellas Pharma US INC | $12.87 | 2023 | Veozah |
| Insulet Corporation | $12.19 | 2022 | |
| Endogastric Solutions, INC | $12.04 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.